Relay Therapeutics Inc (RLAY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Relay Therapeutics Inc (RLAY) has a cash flow conversion efficiency ratio of -0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-51.11 Million) by net assets ($642.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Relay Therapeutics Inc to measure how much of total assets are equity-financed.
Relay Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Relay Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Relay Therapeutics Inc (RLAY) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Relay Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relay Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Dingsheng New Material Joint-Stock Co Ltd
SHG:603876
|
0.012x |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
N/A |
|
National HealthCare Corporation
NYSE MKT:NHC
|
0.058x |
|
Empresas CMPC
SN:CMPC
|
0.007x |
|
First BanCorp
F:OLWN
|
0.072x |
|
NMI Holdings Inc
NASDAQ:NMIH
|
0.000x |
|
ERMENEGILDO ZEG.DL -0001
F:JN0
|
N/A |
|
ADEIA CORP
NASDAQ:ADEA
|
0.125x |
Annual Cash Flow Conversion Efficiency for Relay Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Relay Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Relay Therapeutics Inc (RLAY) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $567.06 Million | $-235.46 Million | -0.415x | -29.65% |
| 2024-12-31 | $777.79 Million | $-249.11 Million | -0.320x | +19.80% |
| 2023-12-31 | $752.00 Million | $-300.32 Million | -0.399x | -65.36% |
| 2022-12-31 | $950.22 Million | $-229.49 Million | -0.242x | -191.42% |
| 2021-12-31 | $897.81 Million | $-74.41 Million | -0.083x | +38.28% |
| 2020-12-31 | $763.29 Million | $-102.49 Million | -0.134x | -136.63% |
| 2019-12-31 | $-180.44 Million | $-66.13 Million | 0.367x | -7.88% |
| 2018-12-31 | $-110.93 Million | $-44.13 Million | 0.398x | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more